By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Obstructive sleep apnea happens when a person's upper airway ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment.

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...